When do biologic drug patents expire and when will biosimilars launch?

United States Patent 10,434,176 Claims and Patent Landscape Analysis (US)

Executive summary: US Patent 10,434,176 protects a specific drug-related invention via claims that include composition and/or method-of-use elements (as defined in the asserted claim set). The US patent estate around 10,434,176 should be evaluated through (1) its claim-dependent structure, (2) its priority and continuations family boundaries, (3) expiration and exclusivity exposure tied to the relevant FDA-listed reference product, and (4) the surrounding Orange Book / litigation / assignment context that determines whether generic or biosimilar entrants face design-around space or blocking claims.

What does US Patent 10,434,176 claim and which claim elements control scope?

Answer (featured snippet): The scope of US 10,434,176 is controlled by the independent claim’s core limitations, with dependent claims narrowing the invention by adding additional structural or procedural requirements. Legal strength and enforceability typically track the narrowest claim limitations that map cleanly to accused products or uses.

Which claim types are most likely present in US 10,434,176

Most issued US patents in branded pharma families use one or more of:

Composition claims (active ingredient plus defined excipients, ratios, particle properties, or formulation parameters)
Method-of-use claims (treatment, patient selection, dosing regimens, or therapeutic endpoints)
Process/manufacturing claims (steps, order, parameters)

For US 10,434,176, the operative question for infringement risk is whether the asserted claims are directed to:

A formulation/product structure that a generic must replicate, or
A use/dosing regimen that can be designed around if the generic label is controlled by FDA and prescription practice differs.

How claim dependencies usually affect freedom-to-operate

Claim dependency creates a hierarchy:

Independent claim sets the “center of gravity” for validity and infringement.
Dependent claims define fallback positions and can create non-obviousness support for narrower subject matter during prosecution.
If an accused product omits one limitation, infringement often fails even if it is otherwise similar.

For portfolio strategy, you typically identify:

The minimum limiting features needed to practice the invention.
The most commercially meaningful limitations (for generic design-around) versus the most legally defensive limitations (for validity defense).

How to map claim elements to an accused product

A practical claim mapping approach evaluates each limitation against:

Ingredient identity and form (salt, polymorph, particle size, solvate, stereochemistry)
Quantitative composition (ranges, ratios, thresholds)
Physical properties (dissolution rate, stability, morphology)
Treatment steps (timing, dose levels, administration route)
Patient or disease definitions (biomarkers, severity, inclusion criteria)

What claim elements tend to be attacked

In US pharma patents, the most common invalidity and unenforceability vectors include:

Anticipation (single prior art reference matching every limitation)
Obviousness (combination of references)
Indefiniteness (if key terms like “effective,” “stable,” “improved,” or ranges lack clear boundaries)
Written description / enablement (if claim scope outstrips support)

What is the priority date, prosecution history posture, and how does that affect validity risk?

Answer: A patent’s priority date governs the novelty window for anticipation and the obviousness combinability for 35 USC 103. The family’s continuation history affects claim breadth and the ability to argue for narrower coverage as a defense.

Priority, continuations, and family boundaries

US 10,434,176 should be assessed as part of its complete priority chain:

Nonprovisional filing dates
Continuations/divisionals that may carry forward narrower subject matter
Terminal disclaimer / PTA adjustments that affect effective expiration

Prosecution indicators that matter

For risk analysis, key prosecution signals include:

Amendment strategy (did the patentee narrow claims to overcome prior art?)
References cited during allowance (indicates where examiners saw risk)
Whether claims survived via argument or amendment

These factors help predict whether:

Prior art exists that can invalidate independent claims, or
Only narrower dependent claims remain defensible.

When does US 10,434,176 expire, and what exclusivity could extend or shorten launch risk?

Answer: Patent expiration is driven by the earliest effective filing date and any adjustments, while market exclusivity is driven by FDA regulatory milestones (NCE/BE exclusivity, patent term extension, pediatric exclusivity). The exclusivity and patent stack determine when a generic can file and when it can market.

Patent term fundamentals

US utility patent term is generally 20 years from earliest nonprovisional filing subject to adjustments.
Patent Term Adjustment (PTA) can extend term for USPTO delay.
Terminal disclaimers can cut extension if family is disclaimed.

FDA exclusivity and Orange Book patent listings

For pharma products, the exclusivity timeline must be aligned to:

Approved NDA/BLA
Orange Book listed patents tied to that approved drug
Listing type: formulation vs method-of-use vs packaging

Launch scenario timing logic

A generic/biosimilar timeline analysis typically follows:

Patent expiration plus PTA impacts when marketing can occur.
If a Paragraph IV is filed, the first applicant can obtain exclusivity after 180-day triggers if conditions are met.
For method-of-use patents, FDA labeling design and carve-outs can materially change launch feasibility.

What is the Orange Book status of the drug covered by US 10,434,176?

Answer: Orange Book status determines whether US 10,434,176 is listed as an enforceable patent for the specific FDA product that a generic would challenge.

How to use Orange Book listings in FTO and litigation planning

When US 10,434,176 is listed:

Determine whether it is tied to drug substance, formulation, or method-of-use
Identify the listed NDA/BLA and strength/route match
Determine whether the generic applicant must certify to 1, 2, 3, or 4 for each listed patent

When it is not listed:

The patentee can still enforce unlisted patents in district court, but the FDA litigation leverage is weaker and generic labeling timing can differ.

How many other patents are in the same estate as US 10,434,176?

Answer: Patent estates are typically multi-layered: the core patent usually sits within a family containing continuations and related jurisdictions, plus follow-on patents on formulation refinement, dosing, biomarkers, or process improvements.

Estate characterization framework

For each family member, catalog:

Publication number(s) and issuance numbers
Claim categories (composition, method-of-use, process)
Priority and continuations
Terminal disclaimer links
Jurisdictions covered (US only vs PCT and EP/WO)

Why estate size matters

A large estate with overlapping claim scope can reduce generic design-around options.
A fragmented estate with narrow, separate “tiles” can allow targeted invalidation of a small subset.

Which companies are likely aligned with US 10,434,176 enforcement or challenge?

Answer: Enforcement and challenge align with the patentee and the product’s branded sponsor, while challenges align with generic filers and branded competitors targeting the same therapeutic use and label.

How to assess “who cares” around the patent

Use:

Patent assignee chain (ownership changes)
Assignment dates (often correlated with licensing and litigation)
Litigation parties in related cases involving the same drug or same patent family
Generic applicant identities on the Orange Book list for the same NDA/BLA

What generic entry risks exist for products that compete with the covered indication?

Answer: Risk depends on whether US 10,434,176 is:

A composition/formulation claim (harder to design around if generic must match the same formulation)
A method-of-use claim (often addressable through label carving, carve-out agreements, or dosing changes)
A process claim (usually harder for generic unless manufacturing comparability is tight)

Design-around vectors

For composition patents:

Different salt/polymorph, different excipient profile, different particle size distribution
Modified manufacturing that changes physical characteristics without changing efficacy

For method-of-use:

Different dosing regimen
Different patient selection criteria that changes label content
Changing endpoint phrasing to avoid literal infringement

What patent litigation affects US 10,434,176, including Paragraph IV challenges and settlements?

Answer: Litigation history is the fastest signal of claim enforceability. If US 10,434,176 has been asserted in Hatch-Waxman suits, you can infer which claims are being treated as commercially meaningful.

What to extract from litigation records

For each case involving US 10,434,176 or its family:

Case number and court
Asserted patents and claim count
Parties (brand sponsor vs generic applicant)
Procedural status (dismissed, settled, summary judgment, trial)
Settlement terms (carve-outs, delayed launch dates, license scope)

Why settlements are commercially predictive

Settlements often:

Narrow disputed claims into a practical design-around boundary
Define early launch windows for non-design-around products
Establish “most-favored” or license-like rights that shape competitive behavior

How strong is the patent estate for US 10,434,176 against invalidity attacks?

Answer: Strength is best evaluated as a function of prior art overlap, claim breadth, and family redundancy. A strong estate has multiple independent claim paths that remain non-overlapping with a single prior art disclosure.

Invalidity risk scoring criteria

Overlap with closest prior art: does one reference plausibly map to the independent claim?
Breadth of claim terms: “effective amount,” “improved,” or range language can become attack surfaces.
Claim support in specification: if the specification does not clearly support the full scope, enablement and written description become relevant.
Family consolidation: if continuations were surrendered or narrowed to overcome art, remaining claims may be more defensible but narrower.

What formulations are protected by US 10,434,176 and how does that compare with competing product technologies?

Answer: Formulation protection matters most for product substitution risk. If US 10,434,176 claims specific excipient systems, ratios, or performance metrics, competing technologies that differ on those parameters can reduce infringement exposure.

Formulation design-around comparison checklist

Active form (salt/polymorph)
Excipients (type and ratio)
Release profile (immediate vs extended release, dissolution targets)
Stability metrics (storage conditions, degradation rates)
Manufacturing process parameters that influence physical characteristics

How do method-of-use patents in the estate for US 10,434,176 affect labeling and prescribing?

Answer: Method-of-use claims can drive litigation leverage even when the generic can match the active ingredient, because the generic label must avoid infringement or be carved out by settlement.

Labeling impact logic

FDA label language determines direct infringement risk under “use in practicing” theories.
If the branded sponsor controls key dosing language, generic entry may be blocked or delayed.
If carve-outs exist, litigation can shift to whether the generic’s intended and actual use falls inside claim boundaries.

What are the global implications beyond the US for the same invention as US 10,434,176?

Answer: Global implications hinge on whether the same family entered EP/WO and what those courts or offices did with claim scope.

Cross-jurisdiction dynamics

US claim construction may differ from EPO interpretation of novelty and inventive step.
If EP claims were narrowed or invalidated, US enforcement may face persuasive pressure in settlement dynamics.
If other jurisdictions upheld broader equivalents, global licensing leverage can increase.

Key patent landscape tables

Table 1: Claim-scope audit framework for US 10,434,176 (for infringement and validity mapping)

Claim dependency layer	What to extract	Infringement use	Validity use
Independent claim	Core elements and ranges/thresholds	“All elements” test	Narrowest novelty anchor
Dependent claims	Added limitations (formulation/process/use)	Identify design-around target omissions	Secondary defenses if independent falls
Method steps (if present)	Dosing schedule, patient inclusion, endpoint language	Label carving strategy	Obviousness via protocol combinations
Product parameters (if present)	Particle size, stability, dissolution, identity	Formulation equivalence risk	Enablement and anticipation mapping

Table 2: Timing logic for generic entry vs patent protection

Trigger	Practical effect	Decision point
Patent expiration (incl. PTA)	Last day marketing can be blocked under listed patent	Launch calendar
Orange Book “type”	Composition/formulation vs method-of-use affects design-around	Label strategy
Paragraph IV filing	Can start 180-day exclusivity if successful	Entry timing optimization
Settlement	Carve-out/delay can override strict expiration math	Agreement compliance
Pediatric exclusivity (if applicable)	Can extend FDA exclusivity window	Brand vs generic market timing

Key Takeaways

US 10,434,176 should be treated as a claim-structure-driven asset: infringement and validity outcomes pivot on the independent claim limitations and the dependent fallback narrowing.
Commercial launch risk depends on whether US 10,434,176 is tied to an Orange Book listing and, if so, whether it is formulation/composition versus method-of-use.
Litigation history is the primary indicator of enforceability. The commercial meaning of US 10,434,176 becomes clear when it is asserted in Hatch-Waxman cases and when settlements define carve-outs or launch schedules.
Estate strength is assessed by redundancy: multiple defensible claim lines reduce the probability that a single prior art combination collapses the patent.

FAQs

How does claim construction change infringement risk for US pharma patents like 10,434,176?
What is the difference between formulation patents and method-of-use patents for generic label design-around?
When do Paragraph IV settlements typically delay generic launches relative to patent expiration?
How do PTA and terminal disclaimers affect the effective expiration date in the US for a pharma patent?
What indicators from prosecution history predict whether independent claims are likely to survive obviousness attacks?

References (APA)

United States Patent 10,434,176. (n.d.). United States Patent and Trademark Office.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	July 26, 2007	10,434,176	2036-07-15
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	October 02, 2009	10,434,176	2036-07-15
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	February 07, 2013	10,434,176	2036-07-15
Csl Behring Ag	HIZENTRA	immune globulin subcutaneous (human), 20% liquid	Injection	125350	March 04, 2010	10,434,176	2036-07-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2011104315	⤷ Start Trial
United States of America	9422364	⤷ Start Trial
United States of America	2023083398	⤷ Start Trial
United States of America	2020054748	⤷ Start Trial
United States of America	2017014509	⤷ Start Trial
United States of America	2013017191	⤷ Start Trial
United States of America	12558422	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Summary for Patent: 10,434,176